What is Greenwich Lifesciences Inc's earnings per share (EPS)?

Greenwich Lifesciences Inc (GLSI) reported diluted earnings per share of $-1.43 for fiscal year 2025. This represents a -6.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Greenwich Lifesciences Inc Financials

GLSI

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Greenwich Lifesciences Inc (GLSI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GLSI FY2025 2026-06-04

Greenwich LifeSciences remains a cash-funded R&D enterprise, with new financing repeatedly replacing operating burn as spending scales up.

FY2025 financing inflow of $12.0M more than offset operating cash burn of $9.9M, leaving cash at $6.2M despite a $19.4M net loss; that means the year-end liquidity position was created by fundraising, not by the business funding itself. Compared with FY2023, cash was only slightly below $7.0M while equity shrank to $353K, so cash was preserved but the capital cushion underneath it was largely used up.

The expense base is development-heavy rather than overhead-heavy: FY2025 R&D reached $17.2M versus SG&A of $2.2M, and R&D has exceeded SG&A by a wide margin in each of the last three fiscal years. For a company with no reported revenue in these annual figures, that pattern says resources are aimed mainly at advancing the program, not at maintaining a large operating platform.

Accounting losses are running ahead of cash losses: FY2025 net loss was $19.4M while operating cash outflow was $9.9M, so reported expense is not turning into cash drain one-for-one. Even so, balance-sheet flexibility is now thin, with a current ratio of 1.1x and liabilities of $5.8M against just $353K of equity, a much tighter posture than the near-debt-free balance sheet seen a few years earlier.

Financial Health Signals

Financial Profile 3/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Greenwich Lifesciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Greenwich Lifesciences Inc has elevated debt relative to equity (D/E of 16.49), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Greenwich Lifesciences Inc's current ratio of 1.06 is below the typical benchmark, resulting in a score of 16/100. However, the company holds substantial cash reserves (106% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Returns

Greenwich Lifesciences Inc generates a -5480.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -1916.5% the prior year.

Piotroski F-Score Weak

2/9

Greenwich Lifesciences Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.51x

For every $1 of reported earnings, Greenwich Lifesciences Inc generates $0.51 in operating cash flow (-$9.9M OCF vs -$19.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$19.4M

YoY-11.2%

Greenwich Lifesciences Inc reported -$19.4M in net income in fiscal year 2025. This represents a decrease of 11.2% from the prior year.

EPS (Diluted)

$-1.43

YoY-6.7%

Greenwich Lifesciences Inc earned $-1.43 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 6.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$6.2M

YoY+51.0%

5Y CAGR-26.4%

Greenwich Lifesciences Inc held $6.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

14M

YoY+8.7%

5Y CAGR+3.5%

Greenwich Lifesciences Inc had 14M shares outstanding in fiscal year 2025. This represents an increase of 8.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-5480.6%

YoY-3564.0pp

5Y CAGR-5473.8pp

Greenwich Lifesciences Inc's ROE was -5480.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 3564.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$17.2M

YoY+11.2%

5Y CAGR+74.7%

Greenwich Lifesciences Inc invested $17.2M in research and development in fiscal year 2025. This represents an increase of 11.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

GLSI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$17.2M+11.2%	$15.5M+101.1%	$7.7M+18.9%	$6.5M+81.9%	$3.6M+236.6%	$1.1M
SG&A Expenses	$2.2M+3.3%	$2.2M+32.4%	$1.6M+4.1%	$1.6M+50.7%	$1.0M+28.8%	$806K
Operating Income	-$19.4M-10.3%	-$17.6M-89.1%	-$9.3M-16.0%	-$8.0M-74.9%	-$4.6M-146.7%	-$1.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$19.4M-11.2%	-$17.4M-95.8%	-$8.9M-13.6%	-$7.8M-71.2%	-$4.6M-145.3%	-$1.9M
EPS (Diluted)	$-1.43-6.7%	$-1.34-94.2%	$-0.69-13.1%	$-0.61	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.2M	N/A	$3.3M-4.4%	$3.4M+50.4%	$2.3M	N/A	$2.3M-0.7%	$2.3M
SG&A Expenses	$518K	N/A	$467K+32.3%	$353K-29.1%	$498K	N/A	$437K+23.6%	$354K
Operating Income	-$5.7M	N/A	-$4.2M-3.2%	-$4.0M-46.1%	-$2.8M	N/A	-$2.7M-2.5%	-$2.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.7M	N/A	-$3.7M+1.0%	-$3.7M-36.6%	-$2.7M	N/A	-$2.7M-2.4%	-$2.6M
EPS (Diluted)	$-0.39	N/A	$-0.27+3.6%	$-0.28-33.3%	$-0.21	N/A	$-0.200.0%	$-0.20

GLSI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$6.2M+50.9%	$4.1M-41.5%	$7.0M-48.1%	$13.5M-50.5%	$27.2M-5.1%	$28.7M
Current Assets	$6.2M+51.0%	$4.1M	N/A	N/A	N/A	$28.7M
Cash & Equivalents	$6.2M+51.0%	$4.1M-41.5%	$7.0M-48.1%	$13.5M-50.5%	$27.2M-5.1%	$28.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.8M+82.9%	$3.2M+981.9%	$294K+12.0%	$263K-31.7%	$385K-63.2%	$1.0M
Current Liabilities	$5.8M+82.9%	$3.2M+981.9%	$294K+12.0%	$263K-31.7%	$385K-63.2%	$1.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$353K-61.1%	$909K-86.4%	$6.7M-49.3%	$13.2M-50.8%	$26.8M-2.9%	$27.6M
Retained Earnings	-$87.1M-28.6%	-$67.8M-34.6%	-$50.4M-21.4%	-$41.5M-23.3%	-$33.6M-15.7%	-$29.1M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$10.5M+70.0%	$6.2M+62.3%	$3.8M+21.8%	$3.1M+13.6%	$2.8M-32.8%	$4.1M-29.7%	$5.8M-19.4%	$7.2M
Current Assets	$10.5M+70.0%	$6.2M	N/A	N/A	N/A	$4.1M	N/A	N/A
Cash & Equivalents	$10.5M+70.0%	$6.2M+62.3%	$3.8M+21.8%	$3.1M+13.6%	$2.7M-32.8%	$4.1M-29.7%	$5.8M-19.4%	$7.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.2M-10.1%	$5.8M+188.8%	$2.0M+19.6%	$1.7M-33.9%	$2.6M-19.9%	$3.2M+278.1%	$842K-37.7%	$1.4M
Current Liabilities	$5.2M-10.1%	$5.8M+259.1%	$1.6M-3.8%	$1.7M+17.2%	$1.4M-54.8%	$3.2M+278.1%	$842K-37.7%	$1.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.3M+1392.1%	$353K-83.8%	$2.2M+51.8%	$1.4M+618.0%	$200K-77.9%	$909K-81.8%	$5.0M-15.2%	$5.9M
Retained Earnings	-$92.8M-6.5%	-$87.1M-12.3%	-$77.6M-5.7%	-$73.4M-5.8%	-$69.4M-2.4%	-$67.8M-16.6%	-$58.1M-4.8%	-$55.4M

GLSI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$9.9M-36.4%	-$7.3M-12.2%	-$6.5M-4.5%	-$6.2M-44.5%	-$4.3M-272.2%	-$1.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$12.0M+174.6%	$4.4M	N/A	-$7.5M-365.8%	$2.8M-90.5%	$29.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$7.5M	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$4.7M-48.1%	-$3.2M-18.8%	-$2.7M-19.6%	-$2.2M-21.7%	-$1.8M+1.0%	-$1.9M+28.3%	-$2.6M-146.6%	-$1.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$9.0M+62.8%	$5.5M+65.4%	$3.4M+28.6%	$2.6M+429.7%	$492K+304.2%	$122K-89.7%	$1.2M-57.3%	$2.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GLSI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-5480.6%-3564.0pp	-1916.5%-1783.8pp	-132.7%-73.5pp	-59.2%-42.2pp	-17.0%-10.3pp	-6.7%
Return on Assets	-313.3%+112.0pp	-425.4%-298.3pp	-127.1%-69.1pp	-58.1%-41.3pp	-16.8%-10.3pp	-6.5%
Current Ratio	1.06-0.2	1.28	N/A	N/A	N/A	27.41
Debt-to-Equity	16.49+13.0	3.51+3.5	0.04+0.0	0.020.0	0.01-0.0	0.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-107.3%	N/A	-169.8%+90.6pp	-260.4%+1108.7pp	-1369.1%	N/A	-53.6%-9.2pp	-44.4%
Return on Assets	-53.8%	N/A	-97.5%+22.5pp	-120.0%-20.2pp	-99.8%	N/A	-45.8%-9.8pp	-36.1%
Current Ratio	2.01+0.9	1.06	N/A	N/A	N/A	1.28	N/A	N/A
Debt-to-Equity	0.99-15.5	16.49+15.6	0.92-0.2	1.17-11.6	12.72+9.2	3.51+3.3	0.17-0.1	0.23
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Theratechnologies Inc THTX

$155.9M

Climb Bio CLYM

$624.7M

Alpha Cognition ACOG

$131.5M

Coherus CHRS

$219.0M

Seres Therapeutics Inc MCRB

$61.2M

Frequently Asked Questions

Is Greenwich Lifesciences Inc profitable?

No, Greenwich Lifesciences Inc (GLSI) reported a net income of -$19.4M in fiscal year 2025.

What is Greenwich Lifesciences Inc's return on equity (ROE)?

Greenwich Lifesciences Inc (GLSI) has a return on equity of -5480.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Greenwich Lifesciences Inc's operating cash flow?

Greenwich Lifesciences Inc (GLSI) generated -$9.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Greenwich Lifesciences Inc's total assets?

Greenwich Lifesciences Inc (GLSI) had $6.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Greenwich Lifesciences Inc spend on research and development?

Greenwich Lifesciences Inc (GLSI) invested $17.2M in research and development during fiscal year 2025.

How many shares does Greenwich Lifesciences Inc have outstanding?

Greenwich Lifesciences Inc (GLSI) had 14M shares outstanding as of fiscal year 2025.

What is Greenwich Lifesciences Inc's current ratio?

Greenwich Lifesciences Inc (GLSI) had a current ratio of 1.06 as of fiscal year 2025, which is considered adequate.

What is Greenwich Lifesciences Inc's debt-to-equity ratio?

Greenwich Lifesciences Inc (GLSI) had a debt-to-equity ratio of 16.49 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Greenwich Lifesciences Inc's return on assets (ROA)?

Greenwich Lifesciences Inc (GLSI) had a return on assets of -313.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Greenwich Lifesciences Inc's cash runway?

Based on fiscal year 2025 data, Greenwich Lifesciences Inc (GLSI) had $6.2M in cash against an annual operating cash burn of $9.9M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Greenwich Lifesciences Inc's Piotroski F-Score?

Greenwich Lifesciences Inc (GLSI) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Greenwich Lifesciences Inc's earnings high quality?

Greenwich Lifesciences Inc (GLSI) has an earnings quality ratio of 0.51x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Greenwich Lifesciences Inc?

Greenwich Lifesciences Inc (GLSI) scores 3 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.